Mind Medicine Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ), a US-based biotech company developing psychedelic-inspired therapies, announced on Friday that it has started Phase 2a proof-of-concept (PoC) trial of lysergic acid diethylamide (LSD) in adult patients with attention deficit hyperactivity disorder (ADHD).
The company has activated its first site and patient enrolment is expected to commence immediately.
The Phase 2a PoC trial will be conducted in partnership with the University Hospital Basel in Switzerland and Maastricht University in the Netherlands, and is aimed at assessing the therapeutic utility of repeated low doses of LSD. This is a multicentre, randomised, double-blind, placebo-controlled Phase 2a trial assessing the safety and efficacy of low-dose LSD as treatment for ADHD in adults. The trial is planning to enrol a total of 52 patients that will receive 20µg of LSD (every (dose schedule) or placebo for six weeks (twice a week on a 3/4-day schedule [± 1 day]). Dr. Matthias Liechti, at University Hospital Basel, Switzerland and Dr. Kim Kuypers at Maastricht University, the Netherlands are to head the trial.
TNF Pharmaceuticals showcases isomyosamine's clinical promise at BGS Spring Meeting 2025
Bruker acquires majority stake in RECIPE to expand clinical mass spectrometry diagnostics
Hoth Therapeutics reports positive initial data from Phase 2a pruritus trial
Galmed reveals novel pharmacodynamic blood markers for Aramchol SCD1 inhibitor
Evommune initiates EVO756 Phase 2b trial in adults with chronic spontaneous urticaria
Telix Pharmaceuticals' TLX101 glioma therapy candidate shows promising efficacy
FluoGuide begins phase II trial of FG001 for head and neck cancer
Sanofi advances respiratory pipeline with positive amlitelimab data and expanded clinical programmes
Sumitomo Pharma America signs research and development agreement with NCI
IDEAYA Biosciences advances Phase 3 design for darovasertib in primary uveal melanoma
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Genflow Biosciences enters into AI-driven research agreement with Heureka Labs